How have JSPRW shares performed in 2024?

Jasper Therapeutics' stock was trading at $0.08 at the start of the year. Since then, JSPRW shares have increased by 146.9% and is now trading at $0.1975. View the best growth stocks for 2024 here .

How do I buy shares of Jasper Therapeutics?

Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:JSPRW

Jasper Therapeutics (JSPRW) Stock Price, News & Analysis

→ Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad)

Free JSPRW Stock Alerts

$0.20

0.00 (0.00%)

(As of 10:36 AM ET)

Compare

Today's Range: $0.18
▼
$0.22
50-Day Range: $0.12
▼
$0.24
52-Week Range: $0.04
▼
$0.38

Volume: 9,387 shs
Average Volume: 29,938 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Ownership SEC Filings Short Interest Social Media

Get Jasper Therapeutics alerts:

Ad InvestorPlace

1970’s computer coder Issues Shocking AI Warning

Louis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.

Click here to watch his new video ASAP

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

JSPRW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JSPRW Stock News Headlines

March 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Ayr Wellness (OtherAYRWF) and Jasper Therapeutics (JSPR)

March 9, 2023 | markets.businessinsider.com

Jasper Therapeutics (JSPR) Receives a Buy from Credit Suisse

See More Headlines

Receive JSPRW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:JSPRW
CUSIP: N/A
CIK: 1788028
Web: N/A
Phone: 650-549-1400
Fax: N/A
Employees: 45
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Ronald A. Martell (Age 62)
President, CEO & Director
Comp: $892.45k
Mr. Herbert C. Cross (Age 52)
CFO & Corporate Secretary
Dr. Luca Di Noto Ph.D.
Senior Vice President of Technical Operations
Mr. David Ku M.D.
Vice President of Corporate Development, Portfolio Strategy & Management
Mr. Matthew Ford
Vice President of Human Resources
Dr. Wendy Pang M.D.
Ph.D., Senior Vice President of Research & Translational Medicine
Dr. Edwin Jonathan Tucker M.D. (Age 52)
Chief Medical Officer
Ms. Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality

Key Competitors

View All Competitors

JSPRW Stock Analysis - Frequently Asked Questions

How have JSPRW shares performed in 2024?: Jasper Therapeutics' stock was trading at $0.08 at the start of the year. Since then, JSPRW shares have increased by 146.9% and is now trading at $0.1975.
View the best growth stocks for 2024 here.
How do I buy shares of Jasper Therapeutics?: Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JSPRW) was last updated on 5/9/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial